Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)
Sign Up to like & getrecommendations! Published in 2025 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s522038
Abstract: Background Brigatinib and alectinib are next-generation anaplastic lymphoma kinase inhibitors (ALKis) showing efficacy against naïve and post-crizotinib-treated advanced ALK+ non-small-cell lung cancers (NSCLCs). Real-world data on alectinib efficacy after brigatinib failure are lacking. Methods Alectinib… read more here.
Keywords: brigatinib; advanced alk; alectinib efficacy; post brigatinib ... See more keywords